登录查看更多内容

40,000 MEN TO JOIN NEW NHS ENGLAND ￡75M PROSTATE CANCER PILOT SCHEME

Michael Branagan-Harris

HealthTech Strategist. Former Founder and CEO of Device Access UK - 50+ NICE Approvals - Getting transformative technologies to patients faster

发布日期: 2018年4月10日

MORE than 40,000 men will be recruited into prostate cancer research, in a Government bid to turn the major killer into “a disease that no longer brings fear”.

The ￡75 million plans announced by Theresa May will see thousands of men offered the chance to try new treatments far earlier, while testing new ways to diagnose the disease.

To find out visit the News and Views Section on the Device Access Website www.deviceaccess.co.uk

要查看或添加评论，请登录

Michael Branagan-Harris的更多文章

A new and ambitious Delivery Plan centred on putting patients first, has been published by UK Regulator MHRA

2021年7月5日

A new and ambitious Delivery Plan centred on putting patients first, has been published by UK Regulator MHRA

The MHRA has published a new delivery plan which aims to facilitate the UK life sciences sector and health service to…
NICE Open up consultation on selection of Medical Devices for evaluation

2020年10月8日

NICE Open up consultation on selection of Medical Devices for evaluation

Topic selection consultation closes 19 November 2020 11:59pm NICE would like your views on the proposals for the Centre…
NICE begins phased restart of non-COVID-19 guidance

2020年6月24日

NICE begins phased restart of non-COVID-19 guidance

NICE has begun a phased restart of publishing non-COVID-19 guidance as the NHS and wider health and care system start…
Elective care in the NHS: Reflections on the MedTech sector’s role

2020年6月8日

Elective care in the NHS: Reflections on the MedTech sector’s role

We were delighted to welcome an all-star cast to one of Device Access’ recent webinar in which we discussed the…

1 条评论
NHS Roadmap To Safely Bring Back Routine Operations

2020年5月15日

NHS Roadmap To Safely Bring Back Routine Operations

Health leaders have today set out a series of measures to help local hospitals plan to increase routine operations and…

1 条评论
Important Update on Re-Starting Elective Surgery NHS England Recording Now Available on Spotify

2020年5月8日

Important Update on Re-Starting Elective Surgery NHS England Recording Now Available on Spotify

The input from the Panellists on Wednesday's Device Access Webinar is a must listen to for the MedTech industry eager…

3 条评论
Is this an unprecedented opportunity for the MedTech industry to help increase day case procedures?

2020年5月1日

Is this an unprecedented opportunity for the MedTech industry to help increase day case procedures?

With an NHS waiting list growing day by day due to Covid 19 taking priority, when elective gets switched back on again,…

1 条评论
NICE publishes its first medtech briefing on artificial intelligence software

2020年4月29日

NICE publishes its first medtech briefing on artificial intelligence software

NICE publishes a Medtech Innovation Briefing on artificial intelligence for analysing CT brain scans A piece of…
NHS to benefit from ￡13.4 billion debt write-off - what does this mean for MedTech?

2020年4月3日

NHS to benefit from ￡13.4 billion debt write-off - what does this mean for MedTech?

Health Secretary announces over ￡13 billion of debt will be written off as part of a major financial reset for NHS…

1 条评论
"The hardest part for all global healthcare systems will be dealing with their elective cases post Covid 19"*

2020年3月25日

"The hardest part for all global healthcare systems will be dealing with their elective cases post Covid 19"*

Global healthcare systems including the UK National Health System (NHS) will eventually have to get back to their usual…

1 条评论

See all articles

40,000 MEN TO JOIN NEW NHS ENGLAND ￡75M PROSTATE CANCER PILOT SCHEME

Michael Branagan-Harris

HealthTech Strategist. Former Founder and CEO of Device Access UK - 50+ NICE Approvals - Getting transformative technologies to patients faster

Michael Branagan-Harris的更多文章

社区洞察

其他会员也浏览了

What Is Ovarian Cancer? | Types, and Symptoms

Cancer , What if The Standard of Care is Not Working?

World best Cancer treatment in Israel

【A Case of Bilateral Secondary Pneumothorax Shortly after the Completion of Concurrent Chemoradiotherapy for Tongue Cancer】

We have a lot of newer drugs that have the potential to increase the cure rates for breast cancer: Dr Poovamma CU, Cytecare Hospitals

Don't start a complementary CANCER treatment without Profrsional advice

CXCL12 Retargeting of an Oncolytic Adenovirus Vector to the Chemokine CXCR4 and CXCR7 Receptors in Breast Cancer

Timeless dynamics of prostate cancer

Stay Ahead of Cancer- Time Machine

Michael Branagan-Harris的更多文章

A new and ambitious Delivery Plan centred on putting patients first, has been published by UK Regulator MHRA

NICE Open up consultation on selection of Medical Devices for evaluation

NICE begins phased restart of non-COVID-19 guidance

Elective care in the NHS: Reflections on the MedTech sector’s role

NHS Roadmap To Safely Bring Back Routine Operations

Important Update on Re-Starting Elective Surgery NHS England Recording Now Available on Spotify

Is this an unprecedented opportunity for the MedTech industry to help increase day case procedures?

NICE publishes its first medtech briefing on artificial intelligence software

NHS to benefit from ￡13.4 billion debt write-off - what does this mean for MedTech?

"The hardest part for all global healthcare systems will be dealing with their elective cases post Covid 19"*

社区洞察

其他会员也浏览了

What Is Ovarian Cancer? | Types, and Symptoms

Cancer , What if The Standard of Care is Not Working?

World best Cancer treatment in Israel

【A Case of Bilateral Secondary Pneumothorax Shortly after the Completion of Concurrent Chemoradiotherapy for Tongue Cancer】

We have a lot of newer drugs that have the potential to increase the cure rates for breast cancer: Dr Poovamma CU, Cytecare Hospitals

Don't start a complementary CANCER treatment without Profrsional advice

CXCL12 Retargeting of an Oncolytic Adenovirus Vector to the Chemokine CXCR4 and CXCR7 Receptors in Breast Cancer

Timeless dynamics of prostate cancer

Stay Ahead of Cancer- Time Machine